UMEM Educational Pearls

Category: Neurology

Title: Neuorproective Agents for Ishcemic Stroke

Keywords: neuroprotective agents, NXY-059, stroke, ischemic stroke, SAINT trial (PubMed Search)

Posted: 3/27/2008 by Aisha Liferidge, MD (Updated: 7/5/2020)
Click here to contact Aisha Liferidge, MD

  • Animal models have shown that neuroprotectants, including free radical trapping agents, decrease injury after ischemic stroke.
  • NXY-059 is a promising neuroprotective agent that was studied in the SAINT I and II trials.
  • SAINT I showed that NXY-059 used within 6 hours of ischemic stroke resulted in significant improvement in the primary outcome measure of reduced disability at 90 days.
  • SAINT II was done to confirm the results of SAINT I with a larger study population, but unfortunately did not show any significant difference in mortality between NXY-059 and placebo.  There was also no difference in adverse reactions, however.
  • More research is needed to determine the best neuroprotective agent to be used acutely for ischemic stroke.
  • The future of emergency treatment of ischemic stroke will likely include such agents, to be administered by emergency physicians.